Pharmaceutical

PRISM Next Gen Tech Company Spotlight: The Glimpse Group’s Journey into the Future

Dec 7, 2023

NEW YORK, NY, December 07, 2023 - In the ever-evolving landscape of technological innovation, the Glimpse Group, Inc. (VRAR) emerges as a beacon of creativity and ingenuity, weaving a future where virtual and augmented realities seamlessly blend with our daily lives. Glimpse, combines reality with the extraordinary, allowing for the future to become a tangible reality. https://prismmarketview.com/companies/the-glimpse-group/ Company Snapshot: A Glimpse into Glimpse Group At the heart of...

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

Dec 7, 2023

NEW YORK, NY, December 07, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Kamada Ltd. (Nasdaq: KMDA), a commercial-stage global biopharmaceutical company with a portfolio of products for rare and serious conditions and a leader in the specialty plasma-derived field, today announced it has inked its largest commercial agreement to date, set to take effect in January 2024. https://prismmarketview.com/companies/kamada-ltd/...

PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL

Dec 5, 2023

NEW YORK, NY, December 05, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Altimmune, Inc. (Nasdaq: ALT) which has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. https://prismmarketview.com/companies/altimmune-inc/ The company’s study enrolled 391 subjects with obesity and at least one comorbidity. Over 50% of subjects achieved at least 15% weight loss and over 30% of subjects achieved at...

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

Nov 29, 2023

WARREN, N.J., Nov. 29, 2023 -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the “NYSE Regulation”) has determined to immediately suspend trading in the Company’s common stock from NYSE American, LLC (the “NYSE American”). As previously disclosed, the NYSE...

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

Nov 10, 2023

“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), has received Orphan Drug Designation for its LP-310 drug candidate for oral...

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Oct 23, 2023

Pittsburgh, PA, October 23, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th. Dr. Jonathan Kaufman, CEO of Lipella, said: “2023 continues to be a year of significant milestone achievements for Lipella. Early in the year, we were delighted to report...

NEWSROOM

PRISM Next Gen Tech Company Spotlight: The Glimpse Group’s Journey into the Future

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Contact Us